Subscribe

Hematologic Cancers

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma
By William King
Hematologic Cancers
TON - August 2020, Vol 13, No 4
A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. Read More ›
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
By Charlie Dawson
Hematologic Cancers
TON - August 2020, Vol 13, No 4
According to long-term follow-up data presented at the ASCO 2020 virtual annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). Read More ›
November 4, 2019 — Oncology News & Updates
Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Web Exclusives
  • Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
  • Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda in Advanced Head and Neck Cancers
  • Discussing Costs of Genomic Testing with Patients
Read More ›
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
TON - March 2018, Vol 11, No 1

According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

Read More ›
Older Drugs in “New Clothes” Achieve Superior Outcomes
By Phoebe Starr
Hematologic Cancers
TON - November 2016, Vol 9, No 6
A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML). Read More ›
Noteworthy Numbers: Lymphoma
Noteworthy Numbers: Lymphoma
Hematologic Cancers
TON - September 2016, Vol 9, No 5

Lymphomas, cancers that begin in lymphatic cells of the immune system, can be divided into 2 main categories: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma is a fairly homogeneous disease characterized by the presence of Reed-Sternberg cells. Hodgkin lymphoma is far less common than NHL—approximately 8000 new Hodgkin lymphoma cases are diagnosed in the United States annually compared with over 70,000 new cases of NHL; more than 60 types of lymphoma are included in the NHL category.1 Presented below are a few facts about various forms of lymphoma.

Read More ›
Nivolumab Approved for Patients with Relapsed, Refractory Classical Hodgkin Lymphoma
FDA Updates, Hematologic Cancers, In the News
Web Exclusives
The US Food and Drug Administration has approved nivolumab (Opdivo) for patients with classical Hodgkin Lymphoma that has progressed or relapsed following autologous hematopoietic stem cell transplantation and post-transplant brentuximab vedotin, according to an announcement by the agency. Notably, the intravenous drug was granted accelerated approval, and Breakthrough Therapy Designation. Read More ›
Acute Myeloid Leukemia: Understanding the Patient’s Experience
Acute Myeloid Leukemia: Understanding the Patient’s Experience
By Caroline Helwick
Hematologic Cancers
TON March 2016 Vol 9 No 2
Patients with acute myeloid leukemia (AML) often feel blindsided by their diagnosis, have trouble understanding their treatment choices, and suffer symptoms that are inadequately addressed. This is a patient population with sizable, and unmet, palliative care and psychosocial needs. Read More ›
All-Oral Combination Therapy Shows Promise in Patients with Transplant-Ineligible, Newly Diagnosed MM
Hematologic Cancers
TON March 2016 Vol 9 No 2
An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM). Read More ›
Bortezomib-Based Combination Overcomes Poor Prognosis in Elderly Patients with Newly Diagnosed MM
Hematologic Cancers
TON March 2016 Vol 9 No 2
Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]). Read More ›

Page 1 of 7


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?